Receive up-to-the-minute news updates on the hottest topics with NewsHub. Install now.

Alexion wins early U.S. approval for rare blood disorder drug

December 21, 2018 5:21 PM
100 0

(Reuters) - The U.S. Food and Drug Administration approved on Friday Alexion Pharmaceuticals Inc’s rare blood disorder drug Ultomiris, an early backing that also solidifies the company’s dominant market position.

The company’s flagship drug, Soliris, was the lone FDA-approved treatment for the blood disorder, paroxysmal nocturnal hemoglobinuria (PNH), and raked in $3.13 billion last year, accounting for nearly 89 percent of total revenue.

Read more

Share in social networks:

Comments - 0